Impact of Breast Cancer Treatment on Employment: Results of a Multicenter Prospective Cohort Study (CANTO)

Author:

Dumas Agnes12,Vaz Luis Ines34,Bovagnet Thomas5,El Mouhebb Mayssam24,Di Meglio Antonio4,Pinto Sandrine5,Charles Cecile67,Dauchy Sarah6,Delaloge Suzette3,Arveux Patrick89,Coutant Charles8,Cottu Paul10,Lesur Anne11,Lerebours Florence12,Tredan Olivier13,Vanlemmens Laurence14,Levy Christelle15,Lemonnier Jerome16,Mesleard Christelle16,Andre Fabrice34,Menvielle Gwenn5

Affiliation:

1. Université de Paris, ECEVE UMR 1123, INSERM (National Institute for Health and Medical Research), Paris, France

2. Clinical Research Department, Gustave Roussy, Villejuif, France

3. Breast Cancer Unit, Department of Medical Oncology, Gustave Roussy, Villejuif, France

4. INSERM Unit U 981, Villejuif, France

5. Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Paris, France

6. Department of Supportive Care, Gustave Roussy, Université Paris-Saclay, Villejuif, France

7. Laboratoire de Psychopathologie et Processus de Santé (EA 4057), Université de Paris, Paris, France

8. Clinical Research Department, Centre Georges-François Leclerc, Dijon, France

9. INSERM U1018, Center for Research in Epidemiology and Population Health, Villejuif, France

10. Department of Medical Oncology, Institut Curie, Paris, France

11. Institut de Cancérologie de Lorraine Alexis Vautrin, Vandoeuvre les Nancy, France

12. Department of Medical Oncology, Institut Curie, Saint-Cloud, France

13. Centre Léon Berard, Lyon, France

14. Centre Oscar Lambret, Lille, France

15. Centre François Baclesse, Caen, France

16. UNICANCER, Paris, France

Abstract

PURPOSE Adverse effects of breast cancer treatment can negatively affect survivors’ work ability. Previous reports lacked detailed clinical data or health-related patient-reported outcomes (PROs) and did not prospectively assess the combined impact of treatment and related sequelae on employment. METHODS We used a French prospective clinical cohort of patients with stage I-III breast cancer including 1,874 women who were working and ≥ 5 years younger than legal retirement age (≤ 57 years) at breast cancer diagnosis. Our outcome was nonreturn to work (non-RTW) 2 years after diagnosis. Independent variables included treatment characteristics as well as toxicities (Common Toxicity Criteria Adverse Events [CTCAE] v4) and PROs (European Organization for Research and Treatment of Cancer [EORTC] Quality of life Questionnaires, Breast cancer module [QLQ-BR23] and Fatigue module [QLQ-FA12], Hospital Anxiety and Depression Scale) collected 1 year after diagnosis. Logistic regression models assessed correlates of non-RTW, adjusting for age, stage, comorbidities, and socioeconomic covariates. RESULTS Two years after diagnosis, 21% of patients had not returned to work. Odds of non-RTW were significantly increased among patients treated with combinations of chemotherapy and trastuzumab (odds ratio [OR] v chemotherapy-hormonotherapy: for chemotherapy-trastuzumab, 2.01; 95% CI, 1.18 to 3.44; for chemotherapy-trastuzumab-hormonotherapy, 1.62; 95% CI, 1.10 to 2.41). Other significant associations with non-RTW included grade ≥ 3 CTCAE toxicities (OR v no, 1.59; 95% CI, 1.15 to 2.18), arm morbidity (OR v no, 1.59; 95% CI, 1.19 to 2.13), anxiety (OR v no, 1.47; 95% CI, 1.02 to 2.11), and depression (OR v no, 2.29; 95% CI, 1.34 to 3.91). CONCLUSION Receipt of systemic therapy combinations including trastuzumab was associated with increased odds of non-RTW. Likelihood of unemployment was also higher among patients who reported severe physical and psychological symptoms. This comprehensive study identifies potentially vulnerable patients and warrants supportive interventional strategies to facilitate their RTW.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3